Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.

Fusion Protein Anchored onto Tumor Cells Superantigen- Transmembrane Sequence Antitumor Response Elicited by a

Cloning, expression, purification and the study of immunotherapy status of TGFαL3-SEB chimeric protein in breast cancer treatment

Background & Aim: Bacterial superantigens, stimulate polyclonal T cells irrespective of their antigen specificity, resulting in a massive release of cytokines from T cells and monocytes, and suggest that that they could be candidates of new antitumor agents. Recent attempts have been done to specifically target superantigens towards tumors. Here, we evaluate TGFαL3-SEB fusion protein as a new a...

Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma.

Exosome-based immunotherapy for cancer holds promise, but needs improvements, especially for tumor-derived exosomes. We investigated, whether exosomes derived from IL-12-anchored human renal cancer cells could enhance their immunogenicity and increase induction of specific antitumor response. A mammalian co-expression plasmid of glycolipid-anchored-IL-12 (GPI-IL-12) was constructed by subclonin...

Antitumor Response to a Codon-Optimized HPV-16 E7/HSP70 Fusion Antigen DNA Vaccine

Background: Vaccines based on virus-like particles are effective against Human Papilloma Virus (HPV) infection; however, they have not shown a therapeutic effect against HPV-associated diseases. New immunotherapy strategies based on immune responses against tumor antigens can positively affect the clearance of HPV-associated lesions. Objective: To generate two therapeutic fusion DNA vaccines (o...

Microenvironment and Immunology Localized Immunotherapy via Liposome-Anchored Anti- CD137 þ IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

Immunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent antitumor immune responses in preclinical studies, but their clinical use is limited by inflammatory toxicities that result upon systemic administration. We hypothesized that by rigorously restricting the biodistribution of immunotherapeutic agents to a locally accessible lesion and draining lymph node(s),...